AstraZeneca and Merck have announced overall survival (OS) data from Phase III trial OlympiAD examining Lynparza (olaparib) as a treatment...
Read More...
The post AstraZeneca announces OS data from breast cancer treatment Lynparza appeared first on Drug Development Technology.
Original Article: AstraZeneca announces OS data from breast cancer treatment Lynparza